- On June 10, 2025, Palin Bio announced the transfer of its 21.03% shares from its controlling shareholder to China Biotechnology, changing its actual controller from Shaanxi State Assets to China National Pharmaceutical Group.
- This acquisition may lead to the integration of Palin Bio with Tian Tan Bio, potentially reshaping the competitive landscape in the blood products industry, where both companies currently face competition.
- The deal, valued at 38.44 billion yuan, is expected to enhance market concentration and could allow the combined revenue of the two firms to rival that of Shanghai Raist, the industry leader.
